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Tuberculosis (TB) is the leading cause of death from infectious diseases worldwide. In 2017, 
nearly 1.2 million died and 10 million people were af-
fected.1,2 Zimbabwe is among the world’s 30 high TB 
burden countries.3 Despite declining TB case notifica-
tions in the country, one third of people with the ac-
tive disease remained undiagnosed in 2017.1
Active case finding (ACF) among high-risk groups 
(HRGs) is effective in identifying undiagnosed TB.4–6 
This leads to earlier initiation of treatment and thus 
reduces the time the individual is infectious and the 
risk of community transmission.7 Modelling done in 
high-burden countries has shown that implementing 
ACF over a 10-year period could reduce TB incidence 
and mortality by respectively 27% and 44%.8 ACF is 
essential if global targets of the End TB Strategy are to 
be met.8,9
Zimbabwe’s National TB Programme (NTP) has 
been implementing ACF since 2017, and this is still 
ongoing. The aim is to identify people with undiag-
nosed TB cases in areas with estimated high propor-
tions of HRGs (see Table 1) and improve treatment 
coverage. The WHO is not clear on the most appropri-
ate algorithm to use for ACF in resource-limited coun-
tries with high HIV and TB prevalence.10 Countries are 
encouraged to select an algorithm that meets their pri-
mary objectives for ACF, taking into account their TB 
prevalence, the HRGs being targeted and available 
resources.4,11,12
Around 10% of people diagnosed with active TB 
in some prevalence surveys are asymptomatic.13–15 It 
is difficult to identify TB disease using symptoms 
alone in people living with HIV (PLHIV). PLHIV of-
ten have paucibacillary disease; clinical diagnosis is 
therefore necessary.16,17 As Zimbabwe has a very high 
TB-HIV co-infection rate (71%),1 the NTP designed 
an algorithm18 appreciably different from those rec-
ommended by the WHO4 to address these concerns 
(Table 2).
Literature comparing the yield and cost of 
WHO-recommended algorithms under programme 
conditions is scarce. We found only one study from 
China that used data from elderly people from a TB 
prevalence survey.19 However, the burden of both TB 
and HIV in their study population was much lower 
than that in Zimbabwe.
The ACF project in Zimbabwe is costly and con-
sumes nearly 20% (over US$1.1 million) of the total 
annual funding for TB in Zimbabwe. As this was a 
matter of concern, the NTP requested a review of the 
screening algorithm to determine if a comparable 
number of people with TB could be identified, but at a 
reduced cost. 
The purpose of the present study was to analyse the 
characteristics of the population screened in Zimba-
bwe and use the data to compare the yield and relative 
cost of identifying a case of TB if NTP had used one of 
the three WHO-recommended algorithms.
METHODS
Study design
This was a cross-sectional study using data from the 
Zimbabwe ACF project.
Setting
General country profile
Zimbabwe is a developing country in sub-Saharan Af-
rican (2017 population 17 million).1 In 2017, 22.5% of 
the population lived in extreme poverty, defined as 
households whose per capita consumption is 2100 
calories.20
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Setting: Ten districts and three cities in Zimbabwe.
Objective: To compare the yield and relative cost of 
identifying a case of tuberculosis (TB) using the three 
WHO-recommended algorithms (WHO2b, symptom in-
quiry only; WHO2d, chest X-ray [CXR] after a positive 
symptom inquiry; WHO3b, CXR only) and the Zimbabwe 
active case finding (ZimACF) algorithm (symptom inquiry 
plus CXR) to everyone.
Design: Cross-sectional study using data from the ZimACF 
project.
Results: A total of 38 574 people were screened from 
April to December 2017; 488 (1.3%) were diagnosed 
with TB using the ZimACF algorithm. Fewer TB cases 
would have been diagnosed with the WHO-recommended 
algorithms. This ranged from 7% fewer (34 cases) with 
WHO3b, 18% fewer (88 cases) with WHO2b and 25% 
fewer (122 cases) with WHO2d. The need for CXR ranged 
from 36% (WHO2d) to 100% (WHO3b). The need for 
bacteriological confirmation ranged from 7% (WHO2d) 
to 40% (ZimACF). The relative cost per case of TB diag-
nosed ranged from US$180 with WHO3b to US$565 for 
the ZimACF algorithm.
Conclusion: The ZimACF algorithm had the highest case 
yield, but at a much higher cost per case than the WHO 
algorithms. It is possible to switch to algorithm WHO3b, 
but the trade-off between cost and yield needs to be re-
viewed by the Zimbabwean National TB Programme.
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The public health system comprises four levels—
central (tertiary), provincial, and district hospitals and 
primary health centres. TB services are offered free of 
charge at all public health facilities. Before the imple-
mentation of ACF, diagnosis of TB was mostly based 
on passive case finding (PCF).
Study sites
We used all available programme data from 10 districts 
(Beitbridge, Bubi, Chimanimani, Chiredzi, Masvingo, 
Matobo, Mutare, Nkayi, Sanyati and Zvimba) and 
three cities (Harare, Chitungwiza and Kwekwe) that 
had been screened in 2017. These sites were selected as 
they were estimated to have the highest prevalence of 
undiagnosed TB and targeted HRGs. The data were 
also deemed reliable for our study.
Teams conducting screening used local knowledge 
to identify places that were most likely to have high 
numbers of undiagnosed TB cases in the district or 
city. Poor overcrowded communities, places near 
mines, popular business centres and areas with limited 
access to health services were prioritised. People in 
these communities were sensitised and mobilised to 
come for free TB screening using social media, posters, 
meetings, print and electronic media. No incentives 
were offered.
All people attending the outreach clinics were ini-
tially screened for TB symptoms by nurses. All partici-
pants also underwent digital chest X-ray (CXR), which 
was interpreted by a physician on site. Supervised spot 
sputum samples were collected from all cases of pre-
sumptive TB and sent for bacteriological confirmation 
at the laboratory. Active TB was diagnosed 1) based on 
bacteriological confirmation, i.e., sputum tests positive 
for TB on Xpert® MTB/RIF (Cepheid, Sunnyvale, CA, 
USA); or 2) by the physician based on the patient’s his-
tory, symptoms, signs and CXR findings despite nega-
tive sputum results.
People were also screened for diabetes and human 
immunodeficiency virus (HIV) as important comorbidi-
ties. Those diagnosed with TB were registered and initi-
ated on treatment onsite, and then referred to their 
nearest health facility for treatment follow-up. Those di-
agnosed with HIV or diabetes at the sites were also re-
ferred to the nearest health facility for treatment and fol-
low-up. TB preventive therapy (TPT) was not provided.
Study population
The study population included individuals screened 
for TB by the Zimbabwe ACF Project between April 
and December 2017.
Data source and variables
Project data stored in the central server were used. 
During screening, all data were entered electronically 
on a tablet. Anonymised data on age, sex, TB symp-
toms, CXR findings, bacteriological confirmation, HIV 
status, HRG and TB diagnosis from the people screened 
were extracted. Information on personnel and labora-
tory costs for the project was also collected.
Statistical analysis
We used STATA v13.0 (StataCorp LP, College Station, 
TX, USA) to analyse data. Encoding errors in seven rec-
ords were identified using a logic check and excluded. 
We calculated the proportion diagnosed with active 
TB, number needed to be screened (NNS) and relative 
cost of identifying one case among individuals with 
different characteristics and HRGs.
The data were used to determine the number and 
proportion of people that would be screened for TB 
symptoms and undergo CXR according to each WHO 
algorithm. We also determined the number of pre-
sumptive TB cases that would have been identified af-
ter symptom screening alone, CXR alone or both se-
quentially. We then determined from these cases the 
number who had been diagnosed with active TB.
A McNemar’s test was used to determine whether 
the number of people diagnosed with TB by each of 
the three WHO algorithms was significantly different 
from the Zimbabwe algorithm at 5% significance level. 
The NNS was also calculated for each algorithm.
We estimated the cost per person for conducting 
symptom screening, having a CXR taken and perform-
ing bacteriological testing to confirm diagnosis (Table 
3). We included only operational costs of personnel 
and laboratory consumables. Other costs related to the 
procurement of capital equipment, depreciation, 
maintenance and insurance were assumed to remain 
constant for all the algorithms. Direct or indirect pa-
tient costs were also excluded.
We calculated the relative cost per case diagnosed 
according to each algorithm by dividing the total cost 
of the screening by the number of people diagnosed 
with TB. Sensitivity analysis was conducted to ascer-
tain if our conclusions on relative cost per case for the 
various algorithms remained the same if cost assump-
tions were altered.
Ethics
Ethical clearance was sought and granted before the 
study by the Medical Research Council, Harare, Zimba-
bwe (MRCZ/E/198) and the International Union 
Against Tuberculosis and Lung Disease Ethics Advisory 
Group, Paris, France (02/18).
RESULTS
A total of 38 574 people were screened for TB in Zim-
babwe (Table 4). Almost two thirds (61.6%) of these 
were female. The mean age of the population was 48 
years (standard deviation 21). Active TB was diagnosed 
in 488 (1.3%) persons, 370 (75.8%) of whom were clin-
ically diagnosed and 118 (24.2%) bacteriologically 
confirmed.
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TABLE 1 High-risk groups for TB in Zimbabwe
High-risk groups for TB in Zimbabwe:
• People living with HIV infection
• Contacts of TB patients
• Miners
• Healthcare workers
• People with diabetes mellitus
• Prisoners
• The elderly (65 years)
TB = tuberculosis; WHO = World Health Organization; HIV = human 
immunodeficiency virus.
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The HRGs were not mutually exclusive. Over half (54.9%) of 
the people screened belonged to more than one HRG, while 
41.0% of people screened did not belong to any of the targeted 
groups. In total, individuals with more than one high-risk factor 
were significantly more likely than those who did not belong to 
any HRG to have TB (1.8% vs. 0.6%; P  0.001). The most com-
mon HRGs among the people screened were being a TB contact 
and being HIV-positive. TB was more common among people pre-
viously treated for TB, those who were HIV-positive and miners.
In all the algorithms, symptom screening was the first step, ex-
cept for WHO3b where CXR was used first (Table 5). As per the 
WHO2d algorithm, the lowest number of people would require 
CXR (n = 13 710, 35.5%). With WHO2b algorithm, no CXR would 
be done.
The number of presumptive TB cases (39.6%) requiring bacteri-
ological confirmation was highest with the Zimbabwean algo-
rithm (Table 5). Fewer numbers of presumptive TB cases would 
have been identified with the Zimbabwe algorithm than all three 
WHO algorithms, with WHO2d having the lowest yield (6.7%). 
Table 6 shows that, compared to the number of TB cases diag-
nosed using the Zimbabwean algorithm, all of the three WHO-rec-
ommended screening algorithms would have identified statisti-
cally significantly fewer TB cases (P  0.001). Respectively 7.0%, 
18% and 25% fewer cases were identified using the WHO3b, 
WHO2b and WHO2d algorithms.
The WHO3b algorithm (US$180) had the lowest relative cost 
per case, which would have been more than three times cheaper 
than the Zimbabwean algorithm (US$565). Sensitivity analysis 
showed that despite varying the unit costs used in our model, the 
WHO3b algorithm had a consistently lower cost per case of TB 
diagnosed than the Zimbabwean algorithm.
DISCUSSION
This is the first study to use data from an ACF programme to com-
pare the yield and relative cost of the WHO-recommended ACF 
screening algorithms in a high TB and HIV prevalence setting.
We found that the current Zimbabwe ACF algorithm gave the 
highest yield of TB cases diagnosed. The cost per case was three 
times that of TB diagnosed using the WHO3b algorithm; how-
ever, 7% of active TB cases would be missed if the WHO3b algo-
rithm is used. It is probable that the cases missed would be diag-
nosed later using PCF in public health facilities. A median delay 
of about 4 weeks is expected with PCF compared to only 1 week 
with ACF.21 ACF should complement, rather than replace PCF in 
finding people with TB disease.5,11,12,22
The number of people needing symptom screening, CXR and 
bacteriological confirmation differed according to the algorithm 
used and this impacts the relative cost per case (Table 5). Partici-
pants who did not belong to any HRG had a lower yield of TB 
and thus increased the cost per case diagnosed. Our results in Ta-
ble 4 indicate that compared to people with no high-risk factors, 
those with more than one had a higher yield of TB. Almost three 
times fewer people with more than one risk factor had to be 
screened to find a single case of TB. As this group of people has a 
higher yield and lower NNS, by adopting WHO 3b, which uses 
better targeting, the NTP can reduce staff workload and labora-
tory costs as fewer people would need screening. This would make 
the case-finding programme more cost-efficient.
The relative cost per case of TB diagnosed in this study are 
markedly different from a study carried out in China.19 A similar 
method was used in the Chinese study, but only data from elderly 
people who participated in a TB prevalence survey were analysed. 
In contrast to our study, this earlier study reported that the 
WHO3b algorithm had the best yield, but was also the most ex-
pensive. This is because direct smear microscopy was used for bac-
teriological confirmation, which is substantially cheaper and less 
sensitive than Xpert.23 Unlike in our study, where operational 
staff costs were used to model the cost of a CXR, the China study 
used market costs, which are more expensive. In addition, the 
NNS in the China study was more than double that in our study 
population, reflecting a lower TB prevalence setting. Despite the 
expense, the Chinese study also recommended that the WHO3b 
algorithm be used.
The strengths of our study were that it used all the available 
data from people screened in the Zimbabwean ACF project under 
normal programme conditions. Data were collected electronically 
TABLE 2 Comparison of the screening algorithm used in Zimbabwe in 2017 for TB with three recommended by WHO
Algorithm Step 1 Step 2 Step 3 Step 4
Zimbabwe Symptom enquiry*: if negative 
or positive, go to Step 2
CXR: if either one of Steps 1 or 
2 is positive, go to Step 3
Bacteriological confirmation†: if 
positive, TB diagnosed; if 
negative go to Step 4
Clinical review: physician can 
make a clinical diagnosis of TB 
after reviewing the case
WHO 2b Symptom enquiry*: if positive, 
go to Step 2
Bacteriological confirmation†: if 
positive, TB diagnosed; if 
negative go to Step 3
Clinical review: physician can 
make a clinical diagnosis of TB 
after reviewing the case
WHO 2d Symptom enquiry*: if positive, 
go to Step 2
CXR: if positive, go to Step 3 Bacteriological confirmation†: if 
positive, TB diagnosed; if 
negative go to Step 4
Clinical review: physician can 
make a clinical diagnosis of TB 
after reviewing the case
WHO 3b CXR: if positive, go to Step 2 Bacteriological confirmation†: if 
positive, TB diagnosed; if 
negative go to Step 3
Clinical review: physician can 
make a clinical diagnosis of TB 
after reviewing the case
* Cough of any duration, weight loss, fever, night sweats. The symptom enquiry in Zimbabwe did not include haemoptysis as recommended by the WHO.
† Xpert was used as the diagnostic test of choice for bacteriological confirmation.
TB = tuberculosis; WHO = World Health Organisation; CXR = chest X-ray.
TABLE 3 Indicative cost* per patient screened in Zimbabwe, 2017
Description
Indicative cost per patient screened
$US
Symptom screening 1.85
Chest X-ray 0.93
Bacteriological confirmation† 11.05
* Only operational staff costs and laboratory consumables; capital and maintenance 
costs excluded.
† Xpert used for bacteriological confirmation.
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during screening. Each patient’s file was verified by the team 
leader before the patient was discharged to minimise transcription 
errors. Our study also adhered to the STROBE (Strengthening the 
Reporting of Observational studies in Epidemiology) guidelines.24
Limitations of this study were that the costings model we used 
only generated indicative costs for the various algorithms. This 
means that the costs cannot be used for international compari-
sons or for designing a new programme. Furthermore, results are 
from areas in Zimbabwe with the highest estimated prevalence of 
TB. Care therefore needs to be taken when extrapolating from 
these results to areas with lower TB prevalence. Implementing 
ACF in such settings may not be cost-effective.25 The study popu-
TABLE 5 A comparison of the number of each test that would be required for the four screening algorithms based on data from Zimbabwe 
ACF project, 2017
Algorithm*
Total screened
n
Individuals who underwent 
symptom screening
n (%)†
Individuals who  
underwent CXR
n (%)†
Individuals who underwent 
Xpert testing
n (%)†
Zimbabwean 38 574 38 574 (100) 38 574 (100) 15 260 (39.6)
WHO 2b 38 574 38 574 (100) 0 13 710 (35.5)
WHO 2d 38 574 38 574 (100) 13 710 (35.5) 2 595 (6.7)
WHO 3b 38 574 0 38 574 (100) 4 145 (10.8)
* Zimbabwean algorithm = everyone is screened using both symptoms and chest X-ray and if either are positive, undergo bacteriological confirmation; WHO 2b = people are 
initially screened using symptoms, and if positive, undergo bacteriological confirmation; WHO 2d = people are initially screened for symptoms; those who are symptom 
screen-positive undergo CXR; those with abnormal CXR undergo bacteriological confirmation; WHO 3b = people are initially screened using CXR, and if positive undergo bac-
teriological confirmation.
† Numbers in brackets represent row percentages.
CXR = chest X-ray; WHO = World Health Organization.
TABLE 4 Characteristics of the population screened and cases diagnosed with active TB in Zimbabwe, 2017
Variable
Number screened for TB
n (%)*
Number diagnosed with TB
n (%)†
Number needed to screen
n
Relative cost per case
$US
All clients 38 574 (100) 488 (1.3) 79 565
Sex
 Female 23 761 (61.6) 202 (0.9) 118 820
 Male 14 813 (38.4) 286 (2.0) 52 385
Age group, years
 0–4 271 (0.7) 2 (0.7) 136 1 045
 5–14 1 471 (3.8) 12 (0.8) 123 906
 15–24 2 755 (7.1) 18 (0.7) 153 973
 25–34 6 109 (15.8) 50 (0.8) 122 809
 35–44 7 735 (20.1) 103 (1.4) 75 524
 45–54 6 510 (16.9) 99 (1.5) 66 473
 55–64 5 120 (13.3) 78 (1.5) 66 482
 65 8 603 (22.3) 126 (1.5) 68 527
Number of high-risk factors
 People with no high-risk 
factors 15 819 (41.0) 92 (0.6) 172 1 108
 People with only one 
high-risk factors 1 597 (4.1) 7 (0.4) 228 1 410
 People with >1 high-risk 
factors 21 158 (54.9) 389 (1.8) 54 422
Type of HRG
 Previously treated for TB 2 462 (6.4) 80 (3.3) 31 276
 HIV status
  Positive‡ 6 562 (17.0) 174 (2.7) 38 296
  Negative 29 471 (76.4) 296 (1.0) 100 700
  Unknown 2 541 (6.6) 18 (0.7) 141 952
 Miners 3 439 (8.9) 69 (2.0) 50 397
 Incarcerated 2 076 (5.4) 37 (1.8) 56 451
 TB contacts 7 250 (18.8) 129 (1.8) 56 441
 Health care workers 1 652 (4.3) 11 (0.7) 150 925
 Patients with diabetes§ 911 (2.4) 3 (0.3) 304 2 151
* Numbers in the brackets are column percentages.
† Numbers in the brackets are row percentages.
‡ Self-reported or confirmed status after testing.
§ Self-reported or tested (random blood glucose of >11.1 mmol/l).
TB = tuberculosis; $US = US dollar; HRG = high-risk group; HIV = human immunodeficiency virus.
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lation was purposively sampled high-risk communities, and selec-
tion bias is also obvious in the male/female ratio.
The high number of females tested may reflect differences in 
health-seeking behaviour between men and women. Had more 
men participated, a higher yield would have been expected, and 
hence a lower cost per case across all the algorithms we com-
pared. There was no significant difference in the number of TB 
cases diagnosed by sex across all the algorithms.
A trade-off could be considered by the NTP when selecting 
the most appropriate ACF algorithm. Savings could be used to 
support other components of the programme, particularly TPT 
which is recommended for PLHIV when active TB has been ex-
cluded.18,26 Unfortunately, TPT was not offered and this was a 
missed opportunity. TPT among PLHIV has been shown to re-
duce the overall risk of developing TB by around 35%.8,27 By in-
tegrating TPT within the ACF programme, Zimbabwe could 
have the additional benefit of reducing TB incidence among 
PLHIV.
CONCLUSION
Our study shows that the Zimbabwe ACF algorithm provides the 
highest yield of TB cases diagnosed. The WHO3b algorithm is less 
effective at identifying TB cases, but is three times cheaper. We 
therefore recommend that the Zimbabwean NTP adopt the 
WHO3b algorithm.
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Total screened
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$US
All cases
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WHO 3b 38 547 454† (1.2) 358 (78.9) 96 (21.1) 85 180
* Zimbabwean algorithm = everyone is screened using both symptoms and chest X-ray and if either are positive, undergo bacteriological confirmation; WHO 2b = people are 
initially screened using symptoms, and if positive, undergo bacteriological confirmation; WHO 2d = people are initially screened for symptoms; those who are symptom 
screen-positive undergo CXR; those with abnormal CXR undergo bacteriological confirmation; WHO 3b = people are initially screened using CXR, and if positive undergo bac-
teriological confirmation.
† McNemar’s test showed the number of active TB cases diagnosed was significantly different (P  0.001) compared to the Zimbabwean algorithm.
TB = tuberculosis; $US = US dollars; WHO = World Health Organization.
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Contexte  :  Dix districts et trois villes du Zimbabwe.
Objectif  :  Comparer le rendement et le coût relatif de l’identification 
d’un cas de tuberculose (TB) en utilisant les trois algorithmes 
recommandées par l’Organisation Mondiale de la Santé (OMS) : 
OMS2b, recherche des symptômes seulement; OMS2d, radiographie 
pulmonaire (CXR) après un résultat positif au test de dépistage de 
symptômes ; OMS3b, CXR seule ; et l’algorithme de recherche active 
des cas du Zimbabwe (ZimACF), test de dépistage de symptômes 
plus CXR à tous.
Schéma  :  Etude transversale basée sur les données du projet ZimACF.
Réultats  :  Des 38 574 personnes dépistées entre avril et décembre 
2017, 488 (1,3%) ont eu un diagnostic de TB grâce à l’algorithme 
ZimACF. Avec les algorithmes recommandés par l’OMS, moins de cas 
de TB auraient été diagnostiqués. Ceci allait de 7% (34 cas) de moins 
avec OMS3b, 18% (88 cas) avec OMS2b et 25% (122 cas) avec 
OMS2d. Le besoin de CXR est allé de 36% (OMS2d) à 100% 
(OMS3b). Le besoin de confirmation bactériologique est allé de 7% 
(OMS2d) à 40% (ZimACF). Le coût relatif par cas de TB diagnostiqué 
est allé de 180 $US avec OMS3b à 565 $US pour l’algorithme ZimACF.
Conclusion  :  L’algorithme ZimACF a eu le rendement le plus élevé 
avec un coût par cas beaucoup plus élevé que les algorithmes OMS. 
Le compromis entre coût et rendement doit être revu par le 
Programme national de la lutte contre la Tuberculose qui doit 
envisager la décision de passer à l’algorithme OMS3b.
Marco de Referencia: Diez distritos y tres ciudades de Zimbabwe.
Objetivo: Comparar el rendimiento y el costo relativo de la detección 
de un caso de tuberculosis (TB) al utilizar los siguientes algoritmos 
recomendados por la Organización Mundial de la Salud (OMS): 
OMS2b, investigación de síntomas exclusiva; OMS2d, radiografía de 
tórax (CXR) tras una investigación de síntomas positiva; OMS3b, CXR 
exclusiva; y el algoritmo de búsqueda activa de casos de Zimbabwe 
(ZimACF), investigación de síntomas más CXR para todos.
Método: Fue este un estudio transversal a partir de los datos del 
proyecto ZimACF.
Resultados: Se examinaron 38 574 personas de abril a diciembre 
del 2017 y se diagnosticó tuberculosis en 488 de ellas (1,3%) 
mediante el algoritmo ZimACF. Si se hubiesen utilizado los 
algoritmos recomendados por la OMS se habrían diagnosticado 
menos casos de TB. Las diferencias oscilaron entre 7% casos menos 
(34 casos) con el OMS3b, 18% menos (88 casos) con el OMS2b y 
25% menos (122 casos) con el OMS2d. La necesidad de una CXR 
varió entre 36% (OMS2d) y 100% (OMS3b). La necesidad de 
confirmación bacteriológica osciló entre 7% (OMS2d) y 40% 
(ZimACF). El costo relativo por caso de TB diagnosticado osciló 
entre 180 US$ con el algoritmo OMS3b y 565 US$ con el algoritmo 
ZimACF.
Conclusión: El algoritmo ZimACF ofreció el más alto rendimiento 
diagnóstico, pero con un costo por cada caso detectado mucho más 
alto que con los algoritmos de la OMS. Es importante que el 
Programa Nacional de Tuberculosis examine de nuevo la 
compensación recíproca entre el costo y el rendimiento y considere 
la decisión posible de adoptar el algoritmo OMS3b.
